NANOG-Mediated Senescence Reversal
Re-analysis of Shahini et al. (2021) showing how NANOG protein can reverse cellular aging in muscle cells.
We used Machine Learning to find hidden patterns in 6,613 genes and built interactive tools + AI chatbots to explore the results.
Experimental Design
Model System
Young Myoblasts
Senescent Myoblasts
NANOG Treatment
Key Findings
6,613 genes analyzed across 8 clusters
Cluster 14 contains NANOG (the intervention gene)
843 significant senescence markers identified
1970 Type B genes (dual senescence marker + NANOG responders)
329 early responders show kinetics within 5 days
Mean reversal increases with duration: 7.4% ā 22.0%
Clusters Analyzed
Genes were clustered based on co-expression patterns across young, senescent, and NANOG-treated samples. Cluster 14 is particularly interesting as it contains NANOG itself.
Cluster 1
Cluster 4
Cluster 6
Cluster 7
Cluster 9
Cluster 11
Cluster 14 ā
Cluster 15
Top Priority Genes
Genes ranked by multi-evidence scoring combining network topology, senescence reversal patterns, cluster stability, and statistical significance. Gene types: Type A (reversing markers - therapeutic successes), Type B (off-target responders), Type C (resistant markers - therapy targets).
Gene Priority Scores
Multi-dimensional scoring from network, reversal, stability, statistical, ml analysis evidence
| Rank | Gene | Type | Cluster | Priority | Score | Evidence | |
|---|---|---|---|---|---|---|---|
| #1 | SLC7A14 Type B | Type B | Cluster 1 | HIGH | 0.000 | N R S S M | |
| #2 | PRKG1 Type B | Type B | Cluster 14 | HIGH | 0.000 | N R S S M | |
| #3 | FHDC1 Type B | Type B | Cluster 6 | HIGH | 0.000 | N R S S M | |
| #4 | THRB Type B | Type B | Cluster 1 | HIGH | 0.000 | N R S S M | |
| #5 | CAMK1 Type B | Type B | Cluster 4 | HIGH | 0.000 | N R S S M | |
| #6 | CTSK Type B | Type B | Cluster 1 | HIGH | 0.000 | N R S S M | |
| #7 | GALNT18 Type B | Type B | Cluster 15 | HIGH | 0.000 | N R S S M | |
| #8 | PPIL6 Type B | Type B | Cluster 6 | HIGH | 0.000 | N R S S M | |
| #9 | LINC00856 Type B | Type B | Cluster 1 | HIGH | 0.000 | N R S S M | |
| #10 | TSGA10 Type B | Type B | Cluster 1 | HIGH | 0.000 | N R S S M | |
| #11 | RP11-327F22.1 Type A | Type A | Cluster 6 | HIGH | 0.000 | N R S S M | |
| #12 | ZNF662 Type B | Type B | Cluster 14 | HIGH | 0.000 | N R S S M | |
| #13 | RP11-567C2.1 Type B | Type B | Cluster 6 | HIGH | 0.000 | N R S S M | |
| #14 | KRT18 Type B | Type B | Cluster 6 | HIGH | 0.000 | N R S S M | |
| #15 | NUDT7 Type B | Type B | Cluster 1 | HIGH | 0.000 | N R S S M | |
| #16 | CCDC144A Other | Other | Cluster 15 | HIGH | 0.000 | N R S S M | |
| #17 | GBP5 Type B | Type B | Cluster 6 | HIGH | 0.000 | N R S S M | |
| #18 | TECTA Type B | Type B | Cluster 6 | HIGH | 0.000 | N R S S M | |
| #19 | PITPNM3 Type B | Type B | Cluster 4 | HIGH | 0.000 | N R S S M | |
| #20 | EREG Type B | Type B | Cluster 1 | HIGH | 0.000 | N R S S M |
A Note of Appreciation (From Shahini et al. 2021)
To the entire research team, led by Dr. Stelios T. Andreadis, NIH Grant Owner:
Dr. Stelios T. Andreadis, Aref Shahini, Nika Rajabian, Debanik Choudhury, Shahryar Shahini, Kalyan Vydiam, Thy Nguyen, Joseph Kulczyk, Tyler Santarelli, Izuagie Ikhapoh, Yali Zhang, Jianmin Wang, Song Liu, Aimee Stablewski, Ramkumar Thiyagarajan, Kenneth Seldeen, Dr. Bruce R. Troen, Jennifer Peirick, and Dr. Pedro Lei.
We offer our sincere congratulations to this impressive collaborative team on the publication of your research paper. The successful completion of this valuable work, enabled by the funding and scientific vision of the NIH Grant, speaks volumes about the leadership of Dr. Andreadis and the diligence and expertise of every author.
Furthermore, we deeply appreciate your commitment to open science by publicly sharing your data. This practice significantly enhances the impact and reproducibility of your findings.
Thank you for your excellent and transparent contribution to the scientific community.
Help Us Improve
Your feedback helps us build better tools for aging research